Cardlytics Stock Forecast, Price & News

+6.02 (+5.74 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume244,140 shs
Average Volume458,794 shs
Market Capitalization$3.65 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

Cardlytics logo

About Cardlytics

Cardlytics, Inc. operates an advertising platform within financial institutions digital channels that include online, mobile, email, and various real-time notifications in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.33 out of 5 stars

Business Services Sector

195th out of 505 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

42nd out of 84 stocks

Analyst Opinion: 2.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

Is Cardlytics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardlytics stock.
View analyst ratings for Cardlytics
or view top-rated stocks.

What stocks does MarketBeat like better than Cardlytics?

Wall Street analysts have given Cardlytics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardlytics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Cardlytics

How were Cardlytics' earnings last quarter?

Cardlytics, Inc. (NASDAQ:CDLX) posted its earnings results on Tuesday, May, 4th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.22. The firm earned $53 million during the quarter, compared to analysts' expectations of $51.96 million. Cardlytics had a negative net margin of 34.32% and a negative trailing twelve-month return on equity of 20.85%. The business's revenue was up 16.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.26) EPS.
View Cardlytics' earnings history

How has Cardlytics' stock price been impacted by Coronavirus (COVID-19)?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDLX stock has increased by 142.1% and is now trading at $110.94.
View which stocks have been most impacted by COVID-19

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics issued an update on its second quarter 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $58 million-$65 million, compared to the consensus revenue estimate of $57.41 million.

What price target have analysts set for CDLX?

6 brokers have issued 1 year price targets for Cardlytics' shares. Their forecasts range from $75.00 to $160.00. On average, they expect Cardlytics' stock price to reach $132.17 in the next twelve months. This suggests a possible upside of 19.1% from the stock's current price.
View analysts' price targets for Cardlytics
or view top-rated stocks among Wall Street analysts.

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:
  • Mr. Scott D. Grimes, Co-Founder & Exec. Chairman (Age 58, Pay $316.83k)
  • Ms. Lynne Marie Laube, Co-Founder, CEO & Director (Age 51, Pay $441.39k)
  • Mr. Andrew C. Christiansen, Chief Financial Officer (Age 41, Pay $321.14k)
  • Mr. Kirk L. Somers, Chief Legal & Privacy Officer and Sec. (Age 56, Pay $350.99k)
  • Mr. Peter Davies, Head of Sales Strategy & Operations
  • Mr. Craig Snodgrass, Chief Data Officer (Age 48)
  • Mr. Jared Luskin, Sr. VP of Growth Verticals
  • Mr. Michael Akkerman, Chief Product & Strategy Officer
  • Mr. Ross McNab, Pres of North America Advter.
  • Ms. Emily Flowers, Head of Sales Readiness

What is Scott Grimes' approval rating as Cardlytics' CEO?

63 employees have rated Cardlytics CEO Scott Grimes on Scott Grimes has an approval rating of 86% among Cardlytics' employees.

Who are some of Cardlytics' key competitors?

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), The Walt Disney (DIS), Alibaba Group (BABA), The Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

When did Cardlytics IPO?

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.55%), JPMorgan Chase & Co. (5.68%), Morgan Stanley (3.15%), Lord Abbett & CO. LLC (2.70%), Ameriprise Financial Inc. (1.69%) and Geode Capital Management LLC (1.54%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics

Which major investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Great Lakes Advisors LLC, Ameriprise Financial Inc., JS Capital Management LLC, Bank of New York Mellon Corp, Allianz Asset Management GmbH, Great West Life Assurance Co. Can, and Russell Investments Group Ltd.. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, and Scott D Grimes.
View insider buying and selling activity for Cardlytics
or view top insider-selling stocks.

Which major investors are buying Cardlytics stock?

CDLX stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., BlackRock Inc., Morgan Stanley, Principal Financial Group Inc., Principal Financial Group Inc., TimesSquare Capital Management LLC, and Geode Capital Management LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics
or or view top insider-buying stocks.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $110.94.

How much money does Cardlytics make?

Cardlytics has a market capitalization of $3.65 billion and generates $186.89 million in revenue each year. The company earns $-55,420,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Cardlytics have?

Cardlytics employs 578 workers across the globe.

What is Cardlytics' official website?

The official website for Cardlytics is

Where are Cardlytics' headquarters?

Cardlytics is headquartered at 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at (888) 798-5802 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.